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Two replication-competent CCR5-tropic HIV-1 reporter constructs were developed that 
encode either nanoluciferase (nLuc) or a near-infrared fluorescent protein (iRFP) for in vivo 
imaging of HIV-1 infection in humanized mice. However, the original versions of these reporters 
had reduced expression after 5 weeks post-infection. We hypothesized that CG dinucleotides 
present in the reporter genes could lead to reduced expression. Thus, we eliminated all CG 
dinucleotides with synonymous mutations in the reporter genes. Our objectives were to measure 
the intensities of HIV-1 p24 and reporter expression in the spleens of humanized mice that were 
infected with the original or codon-optimized (CO) reporter viruses. We hypothesized that CO 
reporter viruses would have improved reporter expression and would correlate better with HIV-1 
p24 staining. Spleens were collected from humanized mice that had been infected for 7-15 weeks 
with one of the original reporter viruses or one of the CO reporter viruses. Thin sections of spleen 
were stained with antibodies against HIV-1 p24 and nLuc. Immunofluorescence of p24, nLuc, and 
iRFP was measured by confocal microscopy and analyzed for fluorescence intensity and co-
localization. The intensity of p24 expression was similar in the spleens of mice infected with 
original or the CO HIV-1 reporter viruses. This was consistent with plasma viremia levels 
remaining high for animals infected with either virus. In contrast, the intensity 
of reporter expression was greater in the spleens of humanized mice infected with CO HIV-1 
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reporter viruses compared to mice infected with original HIV-1 reporter viruses. The difference 
was greater for iRFP virus, which originally had 138 CG dinucleotides in the reporter gene, than 
for nLuc virus, which had 38 CG dinucleotides in the reporter gene. These results correlated with 
whole animal reporter imaging. These findings suggest that CG dinucleotide codon removal 
improves the expression of the reporter genes in HIV-infected spleen cells in humanized mice. 
The fluorescence imaging analysis successfully quantified the HIV-1 p24 and reporter gene 
expression in HIV-1 infected mice spleens that can be applicable in other studies. Future in vivo 
imaging studies will be performed using CO reporter viruses. 
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1.0 Introduction 
The human immunodeficiency virus (HIV), which causes acquired immunodeficiency 
syndrome (AIDS), is one of the most serious health and development challenges in the world. 
Approximately 38 million people are currently living with HIV, and tens of millions of people 
have died of AIDS-related causes since the beginning of the epidemic (1). In 2019, 690,000 people 
died of AIDS-related causes and 1.7 million people were newly infected with HIV globally (2). In 
2018, 37,968 people were diagnosed with HIV in the United States (U.S.) and U.S.-dependent 
areas (3). Of the new diagnoses in the US, 69% were among gay and bisexual men, 24% were 
among heterosexuals, and 7% were among people who injected drugs (3).  
There was a 7% increase of HIV diagnoses from 2014-2018 among Black/African 
Americans in the U.S., showing that this subpopulation is disproportionally affected by HIV (4). 
Black/African American male-to-male sexual contact accounted for 37% of new diagnoses and 
Hispanic/Latino male-to-male sexual contact account for 30%, while White male-to-male sexual 
contact accounted for 27% of the new diagnosis (5). There is no effective cure for HIV, but with 
proper medical care, HIV replication can be suppressed.  
According to the Centers for Disease Control and Prevention (CDC), of the estimated 1.1 
million people living with HIV in the U.S. in 2018, 36% were aged 55 and older (4). When the 
HIV/AIDS epidemic started, infected individuals expected to live approximately one or two years. 
The reason there is a larger older population living with HIV is due to antiretroviral therapy (ART) 
that inhibits virus replication. Due to the improvements in the effectiveness of ART, people who 
are diagnosed early and use ART consistently can have long healthy lives. Consequently, nearly 
half of the people living with diagnosed HIV in the United States are aged 50 or older (4).  
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Having a longer life expectancy with HIV means that infected individuals are at risk for 
comorbidities. Despite effective antiretroviral therapy, many studies have suggested that HIV-1 
may increase the risk of chronic comorbid diseases such as hyperlipidemia, atherosclerosis, and 
osteoporosis (6) (7). According to one study, researchers found that HIV-infected people 50 years 
and older who had received an AIDS diagnosis had a mean of 3.4 comorbidities (4). These 
comorbidities include cardiovascular disease, cancers, lung disease, and liver disease (including 
hepatitis C and hepatitis B). Preexisting cardiovascular, hepatic, and metabolic conditions are often 
complicated by HIV infection. In addition to susceptibility to comorbidities, older adults living 
with HIV are at risk of developing cancer (8). According to one study, people living with HIV 
experience a significantly higher incidence of cancer, including melanoma, leukemia, renal, anal, 
liver, lung, mouth, and throat cancers (9). The loss of the CD4+ T cells by HIV is the main reason 
for opportunistic infections and cancers associated with HIV infection.  
HIV is transmitted primarily through blood and genital fluids. It can also be transmitted 
from infected mothers to newborn infants. People can become infected with HIV by direct contact 
with certain body fluids from a HIV-infected person. For transmission to occur, HIV in the fluids 
must come in direct contact with mucous membranes or damaged tissues, or be directly injected 
into the bloodstream of an HIV-negative person. Mucous membranes are found inside the mouth, 
rectum, vagina, and penis. Most HIV transmission occurs through anal or vaginal sex or sharing 
syringes (10).  
HIV is a retrovirus; its genome consists of two identical single-stranded RNA molecules 
that are enclosed within the capsid of the virus particle. HIV replicates in and kills CD4+ T cells, 
which are an important part of the immune system. To enter a cell, HIV must bind and fuse with 
the host cell. The virus binds to the human CD4 receptor and a coreceptor (usually CCR5 or 
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CXCR4) on the host cell. After entry, the viral RNA is converted into DNA by reverse 
transcription. HIV DNA integrates into the host cell chromatin, which is an essential step in the 
retroviral replication cycle. At the chromosomal level, HIV integration is strongly favored in active 
transcription units, which promotes efficient viral gene expression (11). New HIV particles leave 
the host cell by budding and move on to infect other cells (12). Once HIV destroys enough of 
CD4+ cells, the immune system is not effective at combating basic infections and illnesses. Such 
opportunistic infections are more frequent and severe in people with weakened immune systems. 
When a person becomes infected with HIV, the virus attacks and weakens the immune system. 
During this time, the person is at risk of getting life-threatening infections and cancers. When that 
happens, the illness is called acquired immunodeficiency syndrome (AIDS). The HIV-infected 
person is said to have AIDS when they become sick with other specific opportunistic infections or 
when the number of CD4+ T cells has dropped below 200 cells/mm3 (13) .  
According to multiple studies, hyperimmune responses with production of pro-
inflammatory cytokines, such as TNF-α, can lead to greater HIV production and damage of CD4+ 
and CD8+ T cells through apoptosis (14) and immune senescence (15). Immune senescence is the 
aging of the immune system and changes in lymphocytes development and function. Studies have 
shown the absence of the chronic activation in long-term nonprogressors, reflecting low viremia, 
and in natural nonpathogenic simian immunodeficiency virus (SIV) infection of monkeys, which 
have high viremia and no disease (16). These findings suggest that chronic activation leads to 
comorbidities. Thus, due to all the effects that HIV has on the body and immune system, it is 
important to curb the HIV epidemic. 
The U.S. Department of Health and Human Services (DHHS) has launched Ending the 
HIV Epidemic: A Plan for America. DHHS is proposing this opportunity to eliminate new HIV 
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infections in the U.S. The initiative aims to reached 75% reduction in new HIV infections in 5 
years and at least 90% reduction by 2030 (17). The multi-year program will include 48 counties, 
Washington, D.C., San Juan, Puerto Rico, as well as 7 states that have a substantial rural HIV 
burden with additional expertise, technology, and resources that they need to end the HIV 
epidemic. Collaborating agencies include the Centers for Disease Control and Prevention (CDC), 
Health Resources and Services Administration (HRSA), Indian Health Service (IHS), National 
Institutes of Health (NIH), Office of the HHS Assistant Secretary for Health, and Substance Abuse 
and Mental Health Services Administration (SAMHSA). Over a 10 year period, the initiative will 
scale up four science-based strategies that can end the epidemic: diagnose, treat, prevent, and 
respond. Diagnosis will focus on identifying all people with HIV as early as possible after 
infection. The treatment strategy will focus on providing treatments rapidly and effectively to 
achieve sustained viral suppression. Prevention will focus on making sure that people at risk for 
HIV use potent prevention interventions, including pre-exposure prophylaxis (PrEP) to prevent 
HIV transmission. Lastly, the respond strategy will focus on rapidly detecting and responding to 
growing HIV clusters of infection and preventing their spread to others (18). 
A strategy to prevent and decrease the risk of transmission is the use of PrEP. This consists 
of HIV uninfected individuals taking a daily dose of antiretroviral drugs to lower their chances of 
acquiring HIV. PrEP has been proven to be effective among men who have sex with men, and 
CDC has issued interim guidance on its use in this population (19) .Studies have also shown that 
PrEP is effective among heterosexual men and women (20). PrEP reduces the risk of acquiring 
HIV from sexual contact by about 99% when taken as prescribed (21). Among people who inject 
drugs, PrEP reduces the risk of HIV transmission by at least 74% when taken as prescribed (21). 
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While PrEP can play an important role in prevention of HIV, more understanding on how to better 
implement it in high risk populations is needed.  
It is important for people to know their HIV status so they can take antiretroviral therapy 
(ART) to treat HIV if they are infected. The main goal of the treatment is to reduce the virus 
replication to an undetectable level. Taking ART every day can suppress viremia to undetectable 
levels. People who maintain viral suppression can live a long and healthy life (22). Because ART 
reduces HIV replication in the body, the immune system can be preserved and replenish CD4+ 
cells (23). In addition, suppressed individuals have effectively no risk of transmitting HIV to 
uninfected partners. A clinical trial showed that treating people living with HIV early after 
infection reduces the risk of transmitting the virus to others by 96 % (24).  
Although ART can inhibit HIV replication and can prevent disease progression, it is not 
capable of curing HIV infection. The reason for this is that replication-competent HIV DNA can 
persist in cells during many years of ART. If ART is stopped, then HIV replication can continue 
again (25). Latently infected CD4+ T cells are the most studied HIV reservoirs, as they are 
numerous and can harbor integrated HIV DNA that can be induced with an appropriate stimulation 
of the cell (26) (27) (28). Studying these cells can be challenging due to relatively low frequencies 
in an ART-treated individual (approximately 1 infected cell per million CD4+ T cells) and their 
abundance in tissues that are hard to reach (29). To study CD4+ T cell latency, animal models of 
HIV/AIDS can be used.  
An animal model for human disease should mimic the infection of humans as closely as 
possible (30). Animal models are essential for studying HIV-1 therapeutics regimens. The 
infection and treatment of patients cannot be controlled in clinical studies. Furthermore, certain 
procedures and sampling cannot be performed in humans because they might be difficult and 
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unethical. Animal models offer various advantages when it comes to study HIV/AIDS. The current 
types of models are mouse and non-human primate models. Mouse models offer high reproductive 
rates and low maintenance costs (31). These species are distantly related to humans, which means 
that obtaining results for a human disease is not always accurate. Non-human primates are used 
because they are more similar to humans. However, HIV cannot replicate in macaques, requiring 
the use of simian immunodeficiency virus (SIV). SIV is another lentivirus that is closely related 
to HIV. It is endemic in several non-human primate species in Africa, where it does not cause 
immune deficiency despite high levels of replication (32). Zoonotic transmission of SIV into 
humans has been described several times and has given rise to HIV type 1 and HIV type 2 
(32). SIV infection in Asian macaques closely resembles HIV-1 infection in humans and leads to 
the development of opportunistic infections. However, SIV has significant differences from HIV 
(31).  
Another useful way to study HIV is by using humanized mice. Humanized mice carry 
functioning human genes, cells, tissues, and/or organs. Humanized mice are commonly used as 
small animal models in biological and medical research for human therapeutics. We use this mouse 
because HIV requires human CD4+ cells in order to replicate and does not productively infect 
mouse cells (33). Therefore, introduction of human cells into mice is required for HIV infection 
and pathology. To allow replication of HIV in the mouse, scientists used severe combined 
immunodeficient (SCID) mice. They lack lymphocytes, but can be engrafted with human 
peripheral blood mononuclear cells (PBMCs) or human fetal thymus and liver (34). However, T 
cells were not detected to a great extent in the tissues. Another issue was that other human immune 
cells did not develop, and only transient HIV-1 replication could be detected in vivo (30). Multiple 
limitations pushed new advances in the humanized murine models that allowed the models to 
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reconstitute a human immune system and to lead to a sustainable HIV-1 replication (30). For 
example, NSG mice are extremely immunodeficient. They carry two mutations on the NOD/ShiLtJ 
genetic background: severe combined immune deficiency (scid) and a complete null allele of the 
IL2 receptor common gamma chain (IL2rgnull). The scid mutation is in the DNA repair complex 
protein Prkdc and renders the mice B and T cell deficient. The IL2rgnull mutation prevents 
cytokine signaling through multiple receptors, leading to a deficiency in functional NK cells. The 
severe immunodeficiency allows the mice to be humanized with tissues or cells (35). Human 
CD34+ hematopoietic stem cells introduced into NSG mice lead to the development of human 
lymphocytes and myeloid cells in the blood and in lymphoid tissues. Also, HIV-1 infection could 
be sustained at high levels for more than 40 days (36). This allows us to study HIV pathogenesis 
and treatment over a long period of time in animals.  
Noninvasive imaging of viral pathogens in small animal models is a powerful tool used to 
monitor infection in real time. Imaging allows visualization of temporal and spatial progression of 
infection in real time. This is possible due to the high sensitivity and dynamic range of the 
bioluminescent and fluorescent reporter genes. Preserving the native viral genome structure as 
well as using small reporter genes ensures the proper replication of HIV reporter virus (37). A 
previous study demonstrated that noninvasive bioluminescent imaging of HIV encoding nLuc was 
possible (37). nLuc is an ideal candidate for imaging due to its relatively small sequence and its 
150-fold brighter luminescence than fluorescent proteins (38). While it has a large dynamic range 
and a low background, it requires a substrate for imaging that is rapidly metabolized. We also 
sought to develop a fluorescent reporter virus, as it would not require a substrate and infected cells 
could be easily detected. The wavelengths of near-infrared fluorescent proteins range from 650 to 
900 nm and their high brightness makes iRFP a remarkable tool to image in deep tissues (39).  
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Thus, we developed two replication-competent CCR5-tropic HIV-1 reporter 
constructs that encode either nLuc or iRFP for in vivo imaging in humanized mice. However, the 
original versions of these reporters had reduced reporter expression after 5 weeks post-infection 
despite high levels of plasma viremia. A previous study showed that high frequencies of CG  
dinucleotides in HIV-1 were associated with reduced virus replication due to recognition by the 
human zinc finger antiviral protein (ZAP) (40). In mammalian cells, ZAP depletes cytoplasmic 
RNA that is recognized as foreign due to its elevated CG dinucleotide content compared with 
endogenous mRNAs (41). We hypothesized that CG dinucleotides present in the reporter genes 
led to loss of reporter gene expression. 
To test this hypothesis, CG dinucleotides were eliminated with synonymous mutations in 
the reporter genes to improve their expression in vivo. This led to improved in vivo imaging of 
nLuc and iRFP in mice infected with these codon-optimized (CO) reporter viruses. My objectives 
were to measure 1) the frequencies of cells that had detectable HIV-1 capsid (p24) staining cells 
as well as detectable iRFP or nLuc and 2) the intensities of p24, iRFP, and nLuc expression in the 
spleens of humanized mice that were infected with the original or the CO reporter viruses. Our 
expectation was that the CO reporter viruses would have improved iRFP/nLuc expression and 
would correlate better with HIV-1 p24 staining than the original viruses.  
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2.0 Methods  
2.1 Developing the HIV-1 reporter viruses for imaging virus replication and dissemination 
in vivo  
A proviral plasmid encoding HIV-1NL4-BAL (42) was modified to encode nLuc or iRFP 
upstream of an internal ribosome entry site (IRES; 6ATRi) between env and nef using gene 
synthesis (GenScript) in the same manner previously described (43). Subsequently, the nLuc and 
iRFP genes were re-synthesized to remove all CG dinucleotides with synonymous mutations (CO 
viruses). Viruses were produced by transfection of HEK293T cells with proviral plasmids using 
Lipofectamine 2000 (ThermoFisher). Cell culture supernatant containing HIV-1 was filtered 
through a 0.45 m filter, concentrated with Lenti-X (Takara), and frozen in aliquots at -80º C. 
Viruses were titered in duplicate on GHOST cells (44) by limiting dilution and flow cytometry on 
a BD Accuri flow cytometer (BD Biosciences). 
2.2 Humanized CD34+ mouse model 
All animal-related work was conducted according to the Public Health Services guidelines. 
Mice were housed at the University of Pittsburgh Division of Laboratory Animal Resources at the 
UPMC Hillman Cancer Center in accordance with the American Association of Accreditation of 
Laboratory Animal Care standards. All procedures were approved by the University of Pittsburgh 
Institutional Animal Care and Use Committee under protocol 17020145.  
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NSG mice reconstituted with human CD34+ cells were purchased from Jackson 
Laboratory. These mice were challenged intraperitoneally (IP) with 104 infectious units, as 
determined  by the GHOST cell assay, of either nLuc HIV-1 or iRFP HIV-1. Plasma HIV-1 RNA 
was isolated regularly as previously described and quantified by SCA (45). At necropsy (3-12 
weeks post-challenge), portions of spleen tissues were collected at necropsy from all viremic mice 
infected with an original reporter virus (n = 5-6/group) or a CO reporter virus (n = 4/group).  
Plasma viremia and whole body imaging were performed by others in the Ambrose 
laboratory. 
2.3  Tissue fixation and sectioning 
Each tissue was placed in 2% paraformaldehyde and completely submerged in the solution 
for 1-2 hours. After the two hours, the tissue was submerged in 30% sucrose for 24 hours with the 
sucrose changed 2-3 times. A plastic beaker containing 2-methylbutane (Fisher) was placed in an 
ice bucket inside a styrofoam box containing a few inches of liquid nitrogen. Tissue samples were 
placed on a small piece of filter paper with forceps and completely immersed in the cooled 2-
methylbutane for 30 seconds. The samples were removed from the beaker and immersed in the 
liquid nitrogen for an additional 10 seconds. Samples were placed into a cooled storage container 
and stored at -80 C until sectioning. Thin sections (10 m) of spleen were cut with a microtome 
and kept at -20 C until they were ready for use. 
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2.4 Immunofluorescence staining 
Slides were rehydrated with 2 washes of phosphate buffered saline (PBS). Then, they were 
permeabilized with PBS containing 0.1% Triton X-100. Tissues were blocked with buffer 
containing 2% bovine serum albumin (BSA) and 20% donkey or goat serum for 45 minutes. Slides 
were washed 5 times with PBS containing 0.5% BSA (PBB). Staining was performed with 
antibodies against HIV-1 p24 (1:1500; Santa Cruz Biotechnology, clone 24-4) and nLuc (1:1000; 
R & D Systems, clone 965808) for 1 hour, followed by washing with PBB. Incubation with 
secondary antibody was performed for 1 hour with donkey anti-mouse IgG-Cy3 (1:2000; Jackson 
Immunological) or goat anti-mouse IgG-Cy5 (1:1500; Abcam). Slides were washed 5 times with 
PBB and 5 more times with PBS. Hoechst stain was added for 30 seconds to stain the nuclei and 
the sections were washed 5 times with PBS. To adhere the cover class over the sample, a drop of 
gelvatol was used. Slides were stored overnight in the dark to dry.  
2.5 Imaging analysis 
Immunofluorescence of p24, nLuc, and iRFP was measured by confocal microscopy. A 
Nikon A1 spectral inverted confocal microscope with a 40X 1.49 NS oil immersion objective 
(Nikon) was used to acquire images of the fixed tissue samples. LU-NV laser launch (Nikon) was 
used to emit lasers at 405 nm (Hoechst), 561 nm (Cy3), and 640 nm (Cy5/iRFP). For each tissue 
section, multiple images were acquired from different randomly chosen fields of view. NIS-
Elements software (Nikon) was used to analyze fluorescence intensity and frequency of 
fluorescent cells. For analyzing in vivo HIV-1 reporter expression, the entire tissue area was 
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segmented based on Hoechst signal to define each segment as a cell with a nucleus. Then, for each 
respective channel (Cy3.5 for HIV-1 p24 and Cy5 for iRFP or nLuc), positive cells were 
determined. Cells having positive immunofluorescence were selected as binary zones, which were 
converted to regions of interest to measure mean fluorescence intensity of each positive cell with 
iRFP/nLuc and p24 signal. The total number of positive cells analyzed for nLuc and iRFP were 
4131 and 3114, respectively. The total numbers of p24+ cells were 5011 (nLuc virus) and 4462 
(iRFP virus). The average cell frequencies and intensities were determined by Prism (GraphPad) 
and the mean of the averages was plotted per group. Groups were compared using unpaired t tests 
for each measurement using Prism. 
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3.0 Results   
The work described below is comprised of unpublished results recently submitted for 
publication: 
 
Roy CN, Benitez Moreno MA, Kline C, Ambrose Z. CG dinucleotide removal in 
bioluminescent and fluorescent reporters improves HIV-1 replication and reporter gene 
expression for dual imaging in humanized mice, under review. 
 
All tissue staining and analysis was performed by me. In vivo mouse work and microscopy 
was performed by Chandra Nath Roy. Molecular biology and plasma viremia measurements were 
performed by Christopher Kline. 
3.1 Development of reporter HIV-1 
To visualize HIV-infected cells in vivo, the CCR5-tropic replication-competent HIV-1NL4-
BAL molecular clone was engineered to express either nLuc or iRFP (nLuc HIV-1 or iRFP HIV-1, 
respectively; Figure 1), similar to a previously described construct [49]. The reporter genes were 
introduced upstream of the encephalomyocarditis virus internal ribosome entry site (IRES), 
6ATRi, to allow expression of nef. While all viruses replicated with similar kinetics, reporter virus 
production, particularly for iRFP HIV-1, was reduced compared to WT HIV-1 (data not shown).  
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Figure 1. Development of replication-competent HIV-1 reporter viruses. A schematic of the HIV-1 genome shows 
the reporter gene (nLuc or iRFP) and the 6ATRi sequence between env and nef. 
 
High frequencies of CG dinucleotides in HIV-1 have been shown to be associated with 
reduced virus replication due to recognition by human ZAP (40). We hypothesized that CG 
dinucleotides present in the nLuc and iRFP genes could lead to reduced virus replication and 
reporter gene expression. While the HIV-1 gag and pol genes (4509 bp) had a total of 26 CG 
dinucleotides, nLuc (516 bp) and iRFP (936 bp) had 38 and 138 CGs, respectively. Synonymous 
base substitutions were introduced into the reporter genes of nLuc HIV-1 and iRFP HIV-1 to 
remove all CGs. Although the 6ATRi IRES (461 bp) had 21 CG dinucleotides, these were not 
removed to avoid potentially affecting Nef expression. Replication of codon-optimized (CO) 
reporter viruses had similar replication compared to WT HIV-1 and improved replication 
compared to the original reporter viruses (data not shown), showing that fewer CG dinucleotides 
in the reporter viruses resulted in improved replication in vitro. 
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3.2  Removal of CG dinucleotides in reporter genes improved reporter HIV-1 expression in 
vivo 
 
Figure 2. Design of experiments to characterize replication-competent HIV-1 reporter viruses in humanized 
mice. (A) Original or (B) codon-optimized nLuc HIV-1 or iRFP HIV-1 was injected IP into humanized mice. Virus 
replication was measured by qRT-PCR of viral RN. 
 
 
To determine reporter virus replication in vivo, mice engrafted with human CD34+ 
hematopoietic stem cells were injected with either 104 infectious units of nLuc HIV-1 (n = 5) or 
iRFP HIV-1 (n = 6). HIV-1 RNA was quantified weekly in the plasma of the mice for 5 weeks 
post-challenge by quantitative RT-PCR (Figure 2A). A subset of mice was followed until 9-12 
weeks post-challenge. nLuc HIV-1 infected 4/5 mice and iRFP HIV-1 infected all 6 mice, as 
measured by viral RNA present in the plasma (Figure 3A). Plasma viremia plateaued at week 4 
post-infection in the majority of the mice and was maintained stably through at least 9 weeks post-




Figure 3. Low correlation of plasma viremia with in vivo imaging of original HIV-1 reporter viruses. Humanized 
mice were challenged with nLuc HIV-1 (n = 5) or iRFP HIV-1 (n = 6). (A) Plasma viremia was measured by qRT-
PCR.The limit of detection is denoted by the dashed lines. (B) Images of in vivo nLuc or iRFP expression measured 
by whole body imaging. (C) Expression of in vivo nLuc and iRFP expression was quantified at each time point. The 
limit of detection above background signal for total radiance flux is denoted by dashed lines. (D) Correlations of 
reporter gene expression with plasma viremia for all time pointsare shown. Spearman's rank correlation coefficient (r) 
and p values are shown. 
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Whole animal imaging also was performed on the mice prior to infection, 3 and 7 days 
post-infection, and weekly thereafter. Bioluminescence imaging of nLuc HIV-1 in mice showed 
an exponential increase in signal between day 3 until week 3-4 post-challenge, including the one 
mouse with low to undetectable viremia (Figures 3B, 3C). Mouse CR03 did not appear to be 
productively infected based on plasma viremia, yet nLuc expression was high, suggesting that 
CD4+ cells had been transduced but were not producing virus. However, nLuc expression 
decreased thereafter in the mice. In vivo fluorescence imaging of iRFP HIV-1 showed a smaller 
dynamic range compared to nLuc imaging, and iRFP expression peaked at week 3 post-challenge 
in all of the mice and decreased thereafter to undetectable levels despite having relatively high 
viremia (Figures 3B, 3C). While in vivo nLuc expression was generally correlated with plasma 
viremia(p = 0.025), in vivo iRFP expression did not correlate with plasma viremia (p = 0.71), 
particularly after week 4 or 5 post-infection (Figure 3D). These data suggest that the reporter 
viruses replicated in vivo, but reporter gene expression was reduced over time. 
Replication and reporter gene expression of the CO reporter viruses were evaluated in 
humanized mice (n =4 per virus) for up to 15 weeks post-challenge (Figure 2B). In addition, 
antiretroviral therapy (ART), consisting of daily tenofovir and emtricitabine and weekly long-
acting rilpivirine, was administered to the mice between 3-5 weeks post-challenge to suppress 
virus replication. All animals that were injected with CO-nLuc HIV-1 or CO-iRFP HIV-1 became 
viremic prior to ART administration (Figure 4A). Plasma viremia was reduced to undetectable or 
near undetectable levels in all mice during ART. As expected, viremia rebounded in all animals 
after ART cessation. Viremia rebounded to levels higher than pre-ART, suggesting that reservoirs 





Figure 4. Codon optimization improves in vivo replication of HIV-1 reporter viruses. Humanized mice were 
challenged with CO-nLuc HIV-1 (n = 4) or CO-iRFP HIV-1 (n = 4). (A) Plasma viremia was measured by qRT-PCR. 
The limit of detection is denoted by the dashed lines. Grey shading denotes period of ART administration. (B) Images 
of in vivo nLuc or iRFP expression measured by whole body imaging. (C) Expression of in vivo nLuc and iRFP 
expression was quantified at each time point. The limit of detection is denoted by dashed lines. Grey shading denotes 
period of ART administration. (D) Correlation of reporter gene expression with plasma viremia for all time points are 
shown. For CO-iRFP HIV-1, data points from weeks 1-5 (red circles) or weeks 7-14 (black triangles) are separated. 
Spearman's rank correlation coefficient (r) and p values are shown. 
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In vivo nLuc and iRFP expression was observed in all animals challenged with CO viruses 
prior to ART and declined to undetectable levels during ART, mimicking the trends seen for 
plasma viremia (Figures 4B, 4C). Similar to the original iRFP HIV-1 animals, the dynamic range 
for in vivo detection was narrow compared to nLuc. After ART cessation, in vivo reporter virus 
detection increased or remained stable for at least 14 weeks. Reporter expression in animals 
infected with CO-nLuc HIV-1 correlated more strongly with plasma viremia levels (p < 0.0001; 
Figure 4D) compared to the original reporter virus. Interestingly, the overall correlation between 
reporter expression and plasma viremia for mice infected with CO-iRFP HIV-1 was not significant 
(p = 0.2). However, if the data points were separated for prior to and during ART (weeks 1-5) or 
after ART administration (weeks 7-14), the correlation was significant for each data set (p = 0.0028 
and p = 0.046, respectively).  
3.3 Removal of CG dinucleotides in reporter genes improved reporter HIV-1 expression in 
spleen cells of humanized mice 
To evaluate expression of the reporters in the original and CO viruses at the cellular level, 
immunofluorescence was performed on spleens from the animals with productive infection. As 
animal CR03 did not have appreciable viremia, it was removed from analysis. For animals infected 
with the nLuc HIV-1 reporter viruses, staining was performed using antibodies against HIV-1 
capsid (p24) and nLuc (Figure 5). First, expression intensity of the reporters was assessed and 
compared to p24 staining intensity. Intensity of spleen p24 staining showed variation between 
individual cells within a sample and between animals (Figure 6A), but the average mean intensities 
were nearly identical between the original and CO nLuc HIV-1 groups (p = 0.97; Figures 6A, 6B). 
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Figure 5. Reporter gene expression can be detected in HIV-1 infected cells in the spleens of humanized mice.   
 Representative immunofluorescence images of Hoechst (blue), p24 (red), and reporter gene (white) expression in 
spleen sections of mice infected with original (OG) nLuc HIV-1, CO-nLuc HIV-1, OG iRFP HIV-1, or CO-iRFP 
HIV-1. A mouse lacking human cells was used as a negative control. 
The average intensity of spleen nLuc signal in the animals infected with CO-nLuc HIV-1 
was somewhat higher than that in the animals infected with the original reporter virus, but this was 
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not statistically significant (p = 0.14; Figures 6A, 6B). The p24 staining intensity in the spleens 
of animals infected with the original iRFP HIV-1 was very heterogeneous (Figure 6C) and 
significantly higher than the animals infected with original nLuc HIV-1 (p = 0.049). However, 
the difference in average mean intensities between animals infected with the original or the 
CO nLuc HIV-1 was similar (p = 0.87; Figures 6C, 6D). In contrast to nLuc expression, iRFP 
can be visualized without antibodies or substrate (Figure 5). The mean signal intensity was 
significantly higher in animals infected with CO-iRFP HIV-1 than those infected with the 
original virus (p = 0.0081; Figures 6C, 6D). As immunofluorescence imaging appeared to 
show some p24+ cells that were not positive for reporter gene expression in animals that were 
infected with the original reporter viruses, we evaluated the number of p24+ cells that were 
also positive for reporter expression for all animals. While the frequency of double positive 
infected cells was on average approximately 50% for animals infected with the original nLuc 
or iRFP viruses, >90% of p24+ cells also had detectable reporter gene expression in animals 
infected with the CO reporter viruses (Figure 6E). Overall, the in vivo and ex vivo data suggest 
that CG codon optimization of the reporter genes significantly improved their expression.  
The intensity of p24 expression was similar in the spleens of mice infected with original or 
the CO HIV-1 reporter viruses (p = 0.87 for iRFP groups; p = 0.97 for nLuc groups). This was 
consistent with plasma viremia levels remaining high for animals infected with either the original 
or the CO reporter viruses. In contrast, the intensity of iRFP and nLuc expression was greater in 
the spleens of humanized mice infected with CO HIV-1 reporter virus compared to mice infected 
with original HIV-1 reporter virus. The difference was greater for iRFP virus (p = 0.0081), which 
originally had 138 CG dinucleotides in the reporter gene, than for nLuc virus (p = 0.14), which 




Figure 6. Expression of reporter proteins is improved in spleens of humanized mice infected with codon-
optimized HIV-1 reporter viruses.  Mean intensities of p24 and reporter gene expression in spleen cells of mice 
infected with (A) nLuc/CO-nLuc HIV-1 or (C) iRFP/CO-iRFP HIV-1 were measured by immunofluorescence 
imaging. The average mean intensities of p24 and reporter expression in the (B) nLuc/CO-nLuc HIV-1 or (D) 
iRFP/CO-iRFP HIV-1 groups are shown. (E) The frequencies of p24+ cells that were also positive for nLuc or iRFP 
were counted for each animal. The means and standard deviations of each animal or group are shown. The p values 
from t tests are shown for all bar graphs.  
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4.0 Discussion  
In this study we evaluated HIV-1 infection over time by whole-body imaging in humanized 
mice using replication-competent molecular clones encoding either a bioluminescent protein 
(nLuc) or a near-infrared fluorescent protein (iRFP). Both reporter viruses were detectable in 
humanized mice after infection. Removal of CG dinucleotides increased virus replication levels 
of both viruses in vitro. The iRFP gene is twice the size of the nLuc gene but had more than 3.5-
fold the number of CG dinucleotides, which was consistent with greater defects in reporter virus 
replication and in vivo gene expression prior to codon optimization. Removal of CGs significantly 
improved reporter gene expression in vivo. Both the in vivo and ex vivo expression intensity as 
well as the correlation of reporter expression in p24+ cells were improved for both reporter viruses 
after correction of CG dinucleotides.  
For the original reporter viruses, in vivo nLuc expression was generally correlated with 
plasma viremia while in vivo iRFP expression did not correlate with plasma viremia, showing that 
the reporter viruses replicated in vivo but gene expression was reduced over time. We hypothesized 
that due to ZAP recognition of CG dinucleotides present in the reporter genes, nLuc and iRFP is 
removed during replication inside host cells as they are detected as foreign. While plasma viral 
RNA and intracellular p24 expression were not impaired in the original reporter viruses, reporter 
expression was significantly decreased, particularly for iRFP HIV-1. As reporter gene expression 
is derived from the 5' LTR, as are all other viral proteins, it suggests that reporter gene sequences 
may have been mutated or deleted. This could explain the loss of the reporter signal after 5 weeks 
despite detectable virus replication. In fact, it has been shown previously that the majority of HIV-
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1 proviruses acquire deletions over the course of infection (47, 48). It is possible that the majority 
of replication-competent viruses in these mice had detective reporter genes.  
To overcome this problem, we hypothesized that CG dinucleotides present in the 
reporter genes led to loss of reporter gene expression. CG codon optimization of HIV-iRFP led to 
similar intensities of p24 staining and also higher intensities of iRFP expression in the spleens of 
infected animals compared to the original HIV-iRFP. Codon optimized HIV-nLuc led to similar 
intensities of p24 staining and nLuc expression in the spleens of infected animals compared to the 
original HIV-nLuc. Overall, the in vivo and ex vivo data suggest that CG codon optimization of 
the reporter genes significantly improved their expression. The fluorescence image analysis 
methodology successfully quantified the HIV-1 p24 and reporter gene expression in HIV-1 
infected mice spleens that can be applicable in other studies. Future in vivo imaging studies will 
be performed using CO reporter viruses.  
4.1 Public Health Implications  
These results showed that the reporter viruses led to both virus replication and reporter 
gene expression in cells after infection. By removing CG dinucleotides, HIV-1 infection can be 
visualized by noninvasive, whole body imaging in mice containing human immune cells over time 
by reporter expression, which correlates with plasma viremia. The two reporter viruses will 
provide researchers a tool to develop and study antiretroviral therapy and evaluate HIV-1 
persistence and latency. Tracking of both reporter viruses containing different viral sequences may 
allow investigation of two variants within the same animal, such as wild-type and drug-resistant 
viruses. 
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